A brave new framework for glioma drug development
Abstract
Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.
Author
Hotchkiss, Kelly M
Karschnia, Philipp
Schreck, Karisa C
Geurts, Marjolein
Cloughesy, Timothy F
Huse, Jason
Duke, Elizabeth S
Lathia, Justin
Ashley, David M
Nduom, Edjah K
Long, Georgina
Singh, Kirit
Chalmers, Anthony
Ahluwalia, Manmeet S
Heimberger, Amy
Bagley, Stephen
Todo, Tomoki
Verhaak, Roel
Kelly, Patrick D
Hervey-Jumper, Shawn
de Groot, John
Patel, Anoop
Fecci, Peter
Parney, Ian
Wykes, Victoria
Watts, Colin
Burns, Terry C
Sanai, Nader
Preusser, Matthias
Tonn, Joerg Christian
Drummond, Katharine J
Platten, Michael
Das, Sunit
Tanner, Kirk
Vogelbaum, Michael A
Weller, Michael
Whittle, James R
Berger, Mitchel S
Khasraw, Mustafa
Karschnia, Philipp
Schreck, Karisa C
Geurts, Marjolein
Cloughesy, Timothy F
Huse, Jason
Duke, Elizabeth S
Lathia, Justin
Ashley, David M
Nduom, Edjah K
Long, Georgina
Singh, Kirit
Chalmers, Anthony
Ahluwalia, Manmeet S
Heimberger, Amy
Bagley, Stephen
Todo, Tomoki
Verhaak, Roel
Kelly, Patrick D
Hervey-Jumper, Shawn
de Groot, John
Patel, Anoop
Fecci, Peter
Parney, Ian
Wykes, Victoria
Watts, Colin
Burns, Terry C
Sanai, Nader
Preusser, Matthias
Tonn, Joerg Christian
Drummond, Katharine J
Platten, Michael
Das, Sunit
Tanner, Kirk
Vogelbaum, Michael A
Weller, Michael
Whittle, James R
Berger, Mitchel S
Khasraw, Mustafa
Citations
Altmetric:
Date
2024-10-25
Type
Article
Subject
Oncology. Pathology., Neurology, Surgery
Collections
Citation
Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, Lathia J, Ashley DM, Nduom EK, Long G, Singh K, Chalmers A, Ahluwalia MS, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly PD, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns TC, Sanai N, Preusser M, Tonn JC, Drummond KJ, Platten M, Das S, Tanner K, Vogelbaum MA, Weller M, Whittle JR, Berger MS, Khasraw M. A brave new framework for glioma drug development. Lancet Oncol. 2024 Oct;25(10):e512-e519. doi: 10.1016/S1470-2045(24)00190-6.
Journal / Source Title
The Lancet Oncology
DOI
10.1016/S1470-2045(24)00190-6
PMID
39362262
Publisher
Elsevier
Publisher’s URL
http://www.sciencedirect.com/science/journal/14702045